Cannabidiol (Biopharmaceutical Research Company)

N/A

Report date: 2026/05/02 20:00:18
First In Class

Base Information

Drug NameCannabidiol (Biopharmaceutical Research Company)
Drug Alias NameCBDCBD oilCannabidiol Plant ExtractBRC-001
ClassificationNatural product/Extract > Plants extract
Mechanisms of ActionCannabinoid CB2 receptor inverse agonistsCannabinoid CB1 receptor inverse agonistsSerotonin 5-HT1 receptors modulators +[4] 
TargetsCannabinoid CB2 receptorCannabinoid CB1 receptorSerotonin 5-HT1 receptors +[4] 
Therapy Area/IndicationsBreast NeoplasmsCarcinoma, Ductal, Breast
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiopharmaceutical Research Company
China Registration ClassN/A

Develop Information

Active CompaniesBiopharmaceutical Research Company
Inactive CompaniesN/A
Active IndicationsBreast NeoplasmsCarcinoma, Ductal, Breast
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A